Genetic Testing and Counseling to Reduce Diabetic Complications

Plain-language summary

This study evaluated personalized genetic testing and risk counseling aimed at reducing diabetic complications in patients with type 2 diabetes. It enrolled patients aged 40-75 with suboptimal blood sugar control and a history of high blood pressure; one group received personalized risk counseling and the other received usual care. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Chinese University of Hong Kong

Intervention

Personalized Risk Counselling, Normal usual care

Start date

2/17/2015

Estimated completion

12/31/2018

Countries

Hong Kong

Related genes

Locations

• Shatin, Hong Kong

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Adults with type 2 diabetes aged 40-75 who can give informed consent
2. Subjects with no known chronic kidney disease (CKD defined as eGFR\<60ml/min at baseline)
3. Suboptimal glucose control with HbA1c ≥ 7.5%
4. Known history of hypertension including elevated BP ≥140/90 on more than one occasion

Exclusion Criteria:

1. Subjects with known coronary artery disease or coronary revascularisation
2. Subjects with previous history of cerebrovascular accident
3. Subjects with known proliferative retinopathy or previous laser treatment for diabetic retinopathy
4. Subjects with life-threatening conditions including malignancy
5. Subjects with known psychiatric conditions including depression
6. Subjects with significant renal impairment (eGFR\<60ml/min at baseline) or non-diabetic renal disease (e.g. biopsy-proven glomerulonephritis or obstructive uropathy)
7. Subjects with major physical disability